Information  X 
Enter a valid email address

ShieldTherapeutics Ord1.5P (STX)

Related News

17-Feb-2022 11:54 AM

Shield Therapeutics shares fall as guides for sharp 2021 revenue drop

(Alliance News) - Shield Therapeutics PLC's shares tumbled on Thursday after a trading update revealed a substantial, but expected, fall in revenue. The Newcastle, England-based commercial-stage pharmaceutical company said revenue
28-May-2021 09:18 AM

Greg Madison to replace Tim Watts as Shield Therapeutics CEO

Greg Madison has been appointed as CEO of Shield Therapeutics, a commercial stage pharmaceutical company with a focus on addressing iron deficiency, with effect from 1 June 2021. He will also be appointed as a director of the company during June 2021.
21-May-2021 07:28 AM

Shield Therepeutics 'on track' for US drug launch

Shield Therapeutics, a commercial-stage pharmaceutical company with a focus on addressing iron deficiency, remains ?on track' to launch Accrufer in the US by end of June 2021. Since the fundraise in mid-March 2021, preparatory work has accelerated d
15-Jan-2021 02:01 PM

Shield Therapeutics to present at Shares/AJ Bell event

Commercial stage pharma group Shield Therapeutics is taking part in an investor evening hosted by Shares Magazine and AJ Bell. The group, which develops products for iron deficiency such as its Feraccru and Accrufer brands, will be offering investors ins
16-Sep-2020 07:46 AM

Shield Therapeutics swings to profit as revenue jumps

Iron deficiency focused Shield Therapeutics swung to a first-half profit after it posted a large jump in revenue. Pre-tax profit for the six months through June amounted to £2.7m, compared to losses of £4.7m on-year. Revenue rose to £8
01-May-2020 07:42 AM

Shield Therapeutics forecasts fall in revenue after disappointing trial result

Iron deficiency focused Shield Therapeutics said it had seen minimal disruption commercially from the Covid-19 crisis, though it warned of a fall in revenue due to a disappointing trial result. Revenue for the year through December was now expected to be
27-Jan-2020 07:35 AM

Shield Therapeutics sees revenue falling as expected

Iron deficiency focused Shield Therapeutics said it expected to post a fall in revenue that was nevertheless in line with market expectations. Revenue for the year through December was seen falling to £2.9m, down from £11.9m on-year. Cash at
07-Aug-2019 08:13 AM

Shield Therapeutics losses narrow as sales rise, R&D spending falls

Iron deficiency focused Shield Therapeutics booked a narrower first-half loss, as its grew sales and lowered spending on research and development. Pre-tax losses for the six months through June amounted to £2.5m, compared to losses of £8.0m o
26-Jul-2019 09:30 AM

Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics Plc

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 200p (from 88p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
26-Jul-2019 08:36 AM

Shield Therapeutics wins FDA approval for anaemia drug

Pharmaceutical company Shield Therapeutics said it had received FDA approval in the United States for its Feraccru (Accrufer in the US) drug for the treatment of iron deficiency in adults. The company said it was also in discussions with a number of pote
14-May-2019 08:40 AM

Broker Forecast - finnCap issues a broker note on Shield Therapeutics Plc

finnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a corporate investment rating and price target of 200p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
12-Mar-2019 09:30 AM

Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics Plc

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 88p (from 70p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
19-Feb-2019 08:00 AM

Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics Plc

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and raised its price target to 116p (from 80p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
24-Sep-2018 08:20 AM

Broker Forecast - Peel Hunt issues a broker note on Shield Therapeutics Plc

Peel Hunt today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 70p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
20-Sep-2018 08:40 AM

Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics Plc

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and set its price target at 80p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
19-Sep-2018 07:52 AM

Shield Therapeutics posts loss; inks sales pact with Norgine

Shield Therapeutics posted a first-half loss as it continued to invest in bringing its iron deficiency treatments towards commercialisation. The company also announced that it had entered into an exclusive licence agreement with Norgine, where the latter
11-Apr-2018 09:49 AM

Shield Therapeutics losses deepen, to cut headcount and promotional spending

Shield Therapeutics said annual losses deepened and that it would cut jobs and promotional spending to conserve cash, amid headwinds proving up the effectiveness of its Feraccru iron deficiency treatment in the US. Net losses amounted to £19.6m, co
22-Feb-2018 09:23 AM

Shield Therapeutics cuts costs ahead of Feraccru decision

Shield Therapeutics, a commercial stage, pharmaceutical company, is cutting costs ahead of a decision on the future of Feraccru - its lead asset which is approved and marketed in Europe for the treatment of iron deficiency anaemia (IDA), initially in pati
22-Sep-2017 11:00 AM

Broker Forecast - finnCap issues a broker note on Shield Therapeutics Plc

finnCap today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 265p (from 270p). Story provided by StockMarketWire.com...
07-Sep-2017 08:10 AM

Broker Forecast - finnCap issues a broker note on Shield Therapeutics Plc

finnCap today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 270p. Story provided by StockMarketWire.com...
15-Jun-2017 02:15 PM

Shield Therapeutics raises £12m

Shield Therapeutics has announced that the Company has raised approximately £12m (before expenses) through: - a co-ordinated exercise of 6,870,536 existing warrants at an exercise price of 150p per share raising approximately £10.3m - a plac
04-Apr-2017 10:30 AM

Broker Forecast - Liberum Capital issues a broker note on Shield Therapeutics Plc

Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc (LON:STX) and cut its price target to 245p (from 310p). Story provided by StockMarketWire.com...
18-Jul-2016 12:10 PM

Broker Forecast - Canaccord Genuity issues a broker note on Shield Therapeutics Plc

Canaccord Genuity today initiates coverage of Shield Therapeutics Plc (LON:STX) with a buy investment rating and price target of 235p. Story provided by StockMarketWire.com...

a d v e r t i s e m e n t